Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct;17(10):611-629.
doi: 10.1038/s41571-020-0382-2. Epub 2020 Jun 8.

The adenosine pathway in immuno-oncology

Bertrand Allard  1   2 , David Allard  1   2 , Laurence Buisseret  3 , John Stagg  4   5
Affiliations
Review

The adenosine pathway in immuno-oncology

Bertrand Allard et al. Nat Rev Clin Oncol. 2020 Oct.

Erratum in

Abstract

Cancer immunotherapy based on immune-checkpoint inhibition or adoptive cell therapy has revolutionized cancer care. Nevertheless, a large proportion of patients do not benefit from such treatments. Over the past decade, remarkable progress has been made in the development of 'next-generation' therapeutics in immuno-oncology, with inhibitors of extracellular adenosine (eADO) signalling constituting an expanding class of agents. Induced by tissue hypoxia, inflammation, tissue repair and specific oncogenic pathways, the adenosinergic axis is a broadly immunosuppressive pathway that regulates both innate and adaptive immune responses. Inhibition of eADO-generating enzymes and/or eADO receptors can promote antitumour immunity through multiple mechanisms, including enhancement of T cell and natural killer cell function, suppression of the pro-tumourigenic effects of myeloid cells and other immunoregulatory cells, and promotion of antigen presentation. With several clinical trials currently evaluating inhibitors of the eADO pathway in patients with cancer, we herein review the pathophysiological function of eADO with a focus on effects on antitumour immunity. We also discuss the treatment opportunities, potential limitations and biomarker-based strategies related to adenosine-targeted therapy in oncology.

PubMed Disclaimer

References

    1. Wolberg, G., Zimmerman, T. P., Hiemstra, K., Winston, M. & Chu, L. C. Adenosine inhibition of lymphocyte-mediated cytolysis: possible role of cyclic adenosine monophosphate. Science 187, 957–959 (1975). - PubMed
    1. Henney, C. S., Bourne, H. R. & Lichtenstein, L. M. The role of cyclic 3′,5′ adenosine monophosphate in the specific cytolytic activity of lymphocytes. J. Immunol. 108, 1526–1534 (1972). - PubMed
    1. Strom, T. B., Deisseroth, A., Morganroth, J., Carpenter, C. B. & Merrill, J. P. Alteration of the cytotoxic action of sensitized lymphocytes by cholinergic agents and activators of adenylate cyclase. Proc. Natl Acad. Sci. USA 69, 2995–2999 (1972). - PubMed
    1. Blay, J., White, T. D. & Hoskin, D. W. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res. 57, 2602–2605 (1997). - PubMed
    1. Ohta, A. & Sitkovsky, M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414, 916–920 (2001). - PubMed

Publication types

MeSH terms

Substances

Grants and funding